Market Insights Health Pharmaceuticals Vaccines

Other Vaccines - Cambodia

Cambodia

The projected revenue for the Other Vaccines market in Cambodia is expected to reach US$7.17m in 2024.
Furthermore, it is estimated that the revenue will exhibit an annual growth rate (CAGR 2024-2029) of 10.78%, ultimately leading to a market volume of US$11.96m by 2029.
In terms of global comparison, United States is anticipated to generate the highest revenue in this market, amounting to US$24,730.00m in 2024.
Cambodia is seeing a growing demand for other vaccines as the government focuses on improving its healthcare infrastructure.

Key regions: Australia, Brazil, United Kingdom, Europe, Canada

Market

Region

Region comparison

Currency

Analyst Opinion

The demand for Other Vaccines in Cambodia has been growing steadily in recent years due to various factors.

Customer preferences: Cambodian customers have become increasingly aware of the importance of preventive healthcare measures, including vaccination, due to rising healthcare literacy in the country. Additionally, the COVID-19 pandemic has heightened the importance of vaccines, leading to increased demand for all types of vaccines.

Trends in the market: The Other Vaccines market in Cambodia has been expanding due to the introduction of new vaccines, such as the HPV vaccine, which has been recently added to the country's national immunization program. Furthermore, the market has been growing due to the increasing number of private healthcare providers in the country, which has led to greater accessibility and availability of vaccines.

Local special circumstances: Cambodia has a relatively young population, with a median age of 26 years, which means that a significant portion of the population is eligible for vaccination. Additionally, the country has a high incidence of infectious diseases, such as dengue fever and Japanese encephalitis, which has led to greater awareness of the importance of vaccination.

Underlying macroeconomic factors: Cambodia has experienced strong economic growth in recent years, with a GDP growth rate of over 7% in 2019. This has led to increased investment in the healthcare sector, including in the development and distribution of vaccines. Furthermore, the government has been actively promoting vaccination through its national immunization program, which has led to greater awareness and demand for vaccines among the population.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.